Willner & Heller LLC Acquires 15 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Willner & Heller LLC increased its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 3.9% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 399 shares of the biopharmaceutical company’s stock after buying an additional 15 shares during the period. Willner & Heller LLC’s holdings in Regeneron Pharmaceuticals were worth $284,000 at the end of the most recent reporting period.

Other institutional investors have also made changes to their positions in the company. Rakuten Securities Inc. lifted its position in shares of Regeneron Pharmaceuticals by 380.0% in the 3rd quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 19 shares during the period. FSA Wealth Management LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the 3rd quarter valued at $26,000. Fairfield Financial Advisors LTD bought a new stake in shares of Regeneron Pharmaceuticals in the 3rd quarter worth about $37,000. Truvestments Capital LLC acquired a new stake in shares of Regeneron Pharmaceuticals during the third quarter worth approximately $39,000. Finally, Itau Unibanco Holding S.A. acquired a new stake in shares of Regeneron Pharmaceuticals in the second quarter valued at $42,000. 83.31% of the stock is currently owned by institutional investors.

Regeneron Pharmaceuticals Stock Performance

NASDAQ REGN opened at $681.58 on Monday. The company has a market capitalization of $74.90 billion, a price-to-earnings ratio of 16.87, a PEG ratio of 1.60 and a beta of 0.10. The stock has a fifty day simple moving average of $738.60 and a 200 day simple moving average of $949.32. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a twelve month low of $666.25 and a twelve month high of $1,211.20.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on REGN. Cantor Fitzgerald restated a “neutral” rating and set a $1,015.00 target price on shares of Regeneron Pharmaceuticals in a research report on Wednesday, October 23rd. Bank of America reaffirmed an “underperform” rating and set a $565.00 target price on shares of Regeneron Pharmaceuticals in a report on Tuesday, December 10th. Leerink Partnrs downgraded Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 24th. UBS Group lowered Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their price target for the stock from $1,130.00 to $738.00 in a research report on Thursday. Finally, Wells Fargo & Company dropped their price objective on Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating for the company in a report on Friday, January 10th. One analyst has rated the stock with a sell rating, seven have given a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $1,015.38.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.